Table 2 Adverse events during treatment with ramucirumab in patients with advanced hepatocellular carcinoma
Events | All patients (n = 37) | |
|---|---|---|
Any | Grade ≥ 3 | |
Hypertension | 20 (54.0%) | 2 (5.4%) |
Hypoalbuminemia | 15 (40.5%) | 0 |
Proteinuria | 13 (35.1%) | 1 (2.7%) |
Increased aspartate aminotransferase | 12 (32.4%) | 0 |
Edema | 11 (29.7%) | 0 |
Decreased platelet count | 9 (24.3%) | 0 |
Anorexia | 8 (21.6%) | 2 (5.4%) |
Fatigue | 8 (21.6%) | 2 (5.4%) |
Increased alanine aminotransferase | 7 (18.9%) | 0 |
Bleeding | 5 (13.5%) | 1 (2.7%) |
Elevated ammonia | 4 (10.8%) | 0 |
Diarrhea | 3 (8.1%) | 0 |
Increased serum amylase | 2 (5.4%) | 0 |
Anemia | 2 (5.4%) | 0 |
Blood bilirubin | 2 (5.4%) | 0 |
Fever | 2 (5.4%) | 0 |
Infusion reaction | 1 (2.7%) | 0 |
Weight loss | 1 (2.7%) | 0 |
Hyperuricemia | 1 (2.7%) | 1 (2.7%) |